Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $55.56 Consensus Target Price from Analysts

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $55.5556.

Several research firms have recently commented on TERN. Barclays upped their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Truist Financial boosted their price objective on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Citigroup restated an “outperform” rating on shares of Terns Pharmaceuticals in a research note on Wednesday, November 26th. Oppenheimer lifted their target price on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th.

Insider Buying and Selling

In other news, CEO Amy L. Burroughs sold 71,339 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the transaction, the chief executive officer directly owned 138,976 shares of the company’s stock, valued at $5,294,985.60. This represents a 33.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 165,763 shares of company stock valued at $5,752,450 over the last quarter. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after acquiring an additional 770 shares during the period. FNY Investment Advisers LLC purchased a new position in Terns Pharmaceuticals in the 4th quarter valued at approximately $80,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Terns Pharmaceuticals by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock worth $177,000 after purchasing an additional 994 shares during the last quarter. Polymer Capital Management US LLC acquired a new position in Terns Pharmaceuticals during the third quarter worth $76,000. Finally, Tema Etfs LLC purchased a new stake in Terns Pharmaceuticals during the fourth quarter worth $414,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Stock Down 0.2%

TERN stock opened at $34.20 on Friday. The business has a 50 day moving average price of $36.68 and a 200 day moving average price of $18.74. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -33.20 and a beta of -0.28. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $48.26.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03. As a group, sell-side analysts anticipate that Terns Pharmaceuticals will post -1.19 EPS for the current year.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.